{"id":"W2251006715","doi":"10.1016/j.urology.2015.12.003","title":"Nivolumab: The New Second Line Treatment for Advanced Renal-cell Carcinoma Commentary on: Nivolumab Versus Everolimus in Advanced Renal-cell Carcinoma","year":2015,"lang":"en","type":"letter","venue":"Urology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Nivolumab; Medicine; Everolimus; Renal cell carcinoma; Clinical endpoint; Internal medicine; Oncology; Adverse effect; Carcinoma; Urology; Progression-free survival; Immunotherapy; Randomized controlled trial; Overall survival; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002628024,0.000755757,0.001930869,0.0007170144,0.003336209,0.00304057,0.001883306,0.05443091,0.00641717],"category_scores_gemma":[0.01979011,0.0006995501,0.001828537,0.0007621188,0.002170563,0.002997109,0.001509659,0.03956868,0.004692747],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.005882968,"about_ca_system_score_gemma":0.00563449,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.008419241,"about_ca_topic_score_gemma":0.01575023,"domain_scores_codex":[0.9965102,0.00121606,0.0004202642,0.0004061482,0.001003782,0.0004435221],"domain_scores_gemma":[0.9940475,0.003065194,0.0005738447,0.0001084013,0.0009311208,0.001273791],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001256205,0.00003094341,0.0005259322,0.00006256359,0.00002484205,0.001141921,0.00005923651,0.0001070496,0.0001304663,0.001950606,0.9872212,0.0086197],"study_design_scores_gemma":[0.0004329852,0.0002187411,0.001883259,0.0007576072,0.0001148321,0.002663062,0.0002624961,0.0009572022,0.0003561116,0.009403055,0.9828335,0.0001171819],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.000274378,0.001431014,0.00006036737,0.9800827,0.01634039,0.000007896177,0.00006561326,0.00001467175,0.001722975],"genre_scores_gemma":[0.002914167,0.001125832,0.0001095937,0.9503617,0.04173326,0.00001881157,0.00003612236,0.00001373703,0.003686817],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.05443091,"threshold_uncertainty_score":0.04268408,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03346082888958314,"score_gpt":0.2725464474809048,"score_spread":0.2390856185913217,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}